search

Short-Term Impact of PCSK9 Inhibitor Evolocumab on Coronary Plaques and Lipid Profile in CAD Patients

Repatha_Short-Term Effects of PCSK9_banner image
Repatha_evolocumab administration image
Lipid profile changes after PCSK9i dose
Repatha_Lipid profile icon1
LDL cholesterol Repatha_download image
Repatha_line image
Lipoprotein (a) Repatha_download image
Repatha_line image
Malondialdehyde- modified LDL Repatha_download image
A single dose of evolocumab before PCI significantly reduces lipid-core plaques within 2-6 weeks
Repatha_Strike Early Strike Hard logo
PCSK9i: proprotein convertase subtilisin/kexin type 9 inhibitors, NIRS IVUS: Near-Infrared Spectroscopy Intravascular Ultrasound.
GGI-CO-A1-AQS-300038144-LB-L24-0265
For the use of Registered Medical Practitioner of Hospital or Laboratory only
Reference:
Tatsuhiro Kataoka et al., Atherosclerosis, https://doi.org/10.1016/j.atherosclerosis.2024.118581

No result found. Choose another option for better results.

Related Articles

Have You Figured Out the Wide-Spectrum Clinical Advantages of Vonoprazan for Gastric Acid Complications?

Unlock Gastric Relief Secrets with Vonoprazan...

Brought...

Repatha Gateway - Case of Gauri: Recent STEMI and PCI

Gauri, a patient with inferior STEMI, came to ER, underwent PCI, and was hospitalized. Despite...

Repatha Gateway- Tanmay's Case: Multiple MI

Tanmay, a male patient with a history of recurrent myocardial infarctions (MI), presents with severe...

Persistent CV Risk in Elevated Triglycerides Despite Statin Therapy: ICOS Solution

Mr. Basu’s case: a 54-year-old patient with diabetes, hypertension, and hyperlipidemia on statins, evaluated with...

ICOSIFY SYMPOSIA SERIES

HF Peer Webinar

HF Peer Exchange Forum

Navigating Healthcare Legalities

ICOSIFY Symposia Series - 4

Safety and efficacy of dapagliflozin in individuals diagnosed with acute heart failure

Effect of ferric derisomaltose on cardiovascular and non-cardiovascular events in patients with iron deficiency anemia and heart failure

Comparison of an "inclisiran first" approach with standard care for patients diagnosed with atherosclerotic cardiovascular disease

Effect of low-dose colchicine in patients with type 2 diabetes and recent myocardial infarction

Impact of high-dose intravenous iron on treatment outcomes and cardiovascular events in hemodialysis patients with renal anemia

Cardio Metabolic Meet by Prof. Ko Ko, Prof Aung Kyaw Thu, & Dr. Htin Lynn Kyaw

How Long Would It Take for Patients to Respond to Lipid Lowering Therapy in High Risk Patients or Polyvascular Disease? by Dr. M. Srinivasa Rao

What is the Importance of Aggressive Lipid Lowering in Acute Phase Post ACS in High Risk Patient? by Dr. M Srinivasa Rao

Why is it Important to lower LDL in Complex ACS Patient With multiple Risk Factors? by Dr. Jamshed J dalal

How Early Can You Start PCSK9i Post ACS? by Dr. M Srinivasa Rao